Expert Insights

Matthew Matasar, MD, discusses a phase 2 study assessing the safety and efficacy of fixed-duration mosunetuzumab, a CD20-CD3 T-cell-engaging bispecific monoclonal antibody, for relapsed/refractory follicular lymphoma.

Tim Pawlik, MD, explains how he and colleagues used landmark analysis to develop a prognostic model that provides a more dynamic prediction of long-term outcomes for patients undergoing curative-intent surgery for intrahepatic...

Petros Grivas, MD, PhD, shares how he would treat a patient who presented with a new diagnosis of metastatic urothelial cancer and progressed after completing a gemcitabine-cisplatin chemotherapy regimen.

Jean-Pascal Machiels, MD, discusses results from the phase 3 KEYNOTE-412 trial showing the addition of pembrolizumab to chemoradiotherapy is associated with a favorable trend toward improved EFS for patients with locally advanced head and...

Kathleen Moore, MD, gives an overview on recent developments in treatments for advanced stage ovarian cancer, a topic she presented at the 2022 GDU Women’s Oncology virtual meeting.

Helena Yu, MD, discusses the treatment of patients with early-stage EGFR-mutated lung cancer with a focus on improving overall survival, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer meeting in New York.

Othman Al-Sawaf, MD, provides insight into the best use of minimal residual disease in the management of patients with CLL, which he presented at the 2022 Lymphoma, Leukemia & Myeloma Congress.

Asher Chanan-Khan, MD, argues in favor of BTK inhibitors over BCL-2 inhibitors for the frontline treatment of patients with CLL in a debate at the 2022 Lymphoma, Leukemia & Myeloma Congress.

Komal Jhaveri, MD, provides insights and information regarding new and emerging antibody drug conjugate therapies for patients with triple-negative breast cancer, a topic she presented at the 2022 Great Debates & Updates in Women’s Oncology...

Jan Burger, MD, discusses relevant genetic mutations in CLL which may influence treatment decisions and reviews safety and efficacy data on new and emerging targeted agents for these patients, focusing on BTK inhibitors.